Daily Roundup

CSL Invests $355 Million in Rare Disease Treatment

Biotech heavyweight CSL Ltd. is making a significant bet on rare kidney and liver diseases through an exclusive partnership with Alentis Therapeutics. The company will co-develop and co-promote lixudebart, a potential first-in-class treatment currently being tested for conditions like ANCA-associated vasculitis and rapidly progressive glomerulonephritis. CSL is putting up an initial $355 million, with the potential for an additional $1.2 billion in commercial milestone payments down the line. The partnership also includes profit-sharing arrangements, and CSL will bankroll the completion of ongoing Phase 2 trials and planned Phase 3 studies, plus development work for other kidney and liver disease indications.

Gold Miners Report Strong Quarter Results

The gold sector is delivering solid updates. Predictive Discovery Ltd. produced 52,866 ounces of gold in the September quarter, with its Kiniero operation running above nameplate capacity and maintaining impressive 88.3% gold recoveries. The company finished the quarter with a healthy $405 million in cash and bullion. Meanwhile, Capricorn Metals produced 31,218 ounces in Q1 and successfully completed its Karlawinda Expansion Project on schedule and budget. The expansion boosts processing capacity to 6.5 million tonnes per annum, positioning the company to hit its FY27 guidance of 137,000 to 147,000 ounces.

On the exploration front, Predictive Discovery also announced high-grade drilling results at its Kiniéro project, including a standout intercept of 28.35 meters grading 5.87 grams per tonne of gold. The company is planning an aggressive 2027 drilling campaign with approximately 1,800 holes to unlock further resource potential and extend mine life.

Wound Care Breakthrough for Diabetic Patients

Aroa Biosurgery has some encouraging news for diabetic foot ulcer treatment. A randomized controlled trial published in the International Wound Journal shows that its Symphony product significantly improves healing outcomes. When added to standard care, 55% of diabetic foot ulcers achieved complete wound closure within 12 weeks, compared to just 35% with standard care alone. Patients using Symphony also healed faster, with average closure time dropping from 73.2 days to 65.4 days—a meaningful 7.8-day improvement.

Dimerix Marks Four-Year Milestone in FSGS Study

Clinical-stage biotech Dimerix has reached an important milestone with the first patient completing four years in its DMX-200 clinical program for focal segmental glomerulosclerosis. The achievement spans the full two-year ACTION3 Phase 3 trial plus a two-year Open Label Extension study. What's particularly notable is that over 90% of patients who finished the main trial opted to continue into the extension phase, signaling strong confidence in the treatment's safety and efficacy profile. The company is also planning a post-trial access program to provide continued access to DMX-200 pending ethics approval.